Apixaban bests rivaroxaban, on par with dabigatran in reducing stroke, bleeding risks
Use of apixaban for nonvalvular atrial fibrillation (NVAF) appears better than rivaroxaban in reducing the risks of stroke and bleeding but is associated with similar risks relative to dabigatran, a study has shown.
Apixaban bests rivaroxaban, on par with dabigatran in reducing stroke, bleeding risks
26 Jun 2021
